Ritonavir (Norvir): Research
- Intranasal and Topical Corticosteroids and Risk of Cushing's Symptoms in HIV Patients on Ritonavir-Based Combinations (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Case Reports of Complications From Ketamine Use in Two MSM on Ritonavir-Based Combinations (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Warfarin and ARVs: Impact of African-American Race and Ritonavir (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Treatment With a Ritonavir-Boosted Protease Inhibitor During Pregnancy Increases Risk of Preterm Delivery (April 10, 2012)
From aidsmap.com
 Top 10 HIV/AIDS-Related Clinical Developments of 2011 (December 1, 2011)
David Alain Wohl, M.D., on HIV treatment as prevention; the dawning of pre-exposure prophylaxis (PrEP), but with women absent; the concept of "viremia copy-years"; the impact of race and gender on HIV treatment outcomes; setbacks for two treatment approaches involving Isentress; new hepatitis C therapies; a new once-daily HIV pill; the rising rates of HIV among black MSM; and what comes after "test and treat."
From TheBody.com
- Dose Optimisation: 50 mg Ritonavir-Boosting, 3TC Dosing and Raltegravir Once-Daily (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Reyataz/Isentress Combo Spares Norvir and Nukes, but Is Integrase Resistance a Concern? (July 22, 2010)
From AIDSmeds.com
- The Next Generation of Boosters: Promising Data on Potential Alternatives to Ritonavir (February 9, 2009)
Brian Kearney, Pharm.D., of Gilead Sciences Inc., and Robert Guttendorf, Ph.D., of Sequoia Pharmaceuticals discuss encouraging findings from early human trials on a pair of pharmacokinetic enhancers whose utility could potentially extend far beyond protease inhibitor boosting.
In The 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Among Patients on Boosted-PI Regimens, Dose Staggering and Selective Non-Adherence to Ritonavir Is Relatively Common (February 6, 2008)
From TheBodyPRO.com
- Short-Term Ritonavir Exposure Impacts HDL, CD36 and Triglyceride Levels in Healthy Volunteers (February 4, 2008)
Marta Boffito, M.D., Ph.D., discusses her study, which examines the possible role of ritonavir in increasing cardiovascular risk.
From TheBodyPRO.com
- Notice of Important New Drug Interactions With Norvir, Kaletra (March 30, 2005)
New interactions noted with fluticasone (a component of Flonase nasal spray) and trazodone (Desyrel, an antidepressant).
From U.S. Food and Drug Administration
On TheBodyPRO.com
- Drug Development News: Abbott (May/June 2004)
New formulations of lopinavir/ritonavir (Kaletra) and ritonavir are in the works.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Abbott Laboratories Increases Norvir Price Fivefold (December 26, 2003)
John James analyzes the factors that may have played a role in the price hike.
In AIDS Treatment News, from AIDS Treatment News
- Pharmacological and Therapeutic Properties of Ritonavir-Boosted Protease Inhibitor Therapy in HIV-Infected Patients (December 4, 2003)
In Journal of Antimicrobial Chemotherapy
- Ritonavir Has Anti-Cancer Effects (March 12, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Research From the 42nd ICAAC: Extra Ritonavir: Boost or Consequences (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Low-Dose Ritonavir Moderately Enhances Nelfinavir Exposure (October 2002)
An abstract from Clinical Pharmacology & Therapeutics.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
On TheBodyPRO.com
- Ritonavir Can Reduce Kaposi's Sarcoma Risk (July 18, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Efficacy and Safety of Amprenavir/Ritonavir 600/100 mg BID Compared to APV 1,200 mg BID in ART-Experienced and Naive Subjects: ESS40011 (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Preliminary Results of Intensification Therapy With Amprenavir/Ritonavir in Two Different Doses: 1,200/200 QD vs. 600/100 BID in Heavily Pretreated Patients Failing HAART (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
